Atrial fibrillation (AF) affects > 33.5 million people worldwide, a number that is expected to increase significantly in the upcoming years due to the aging of the population and the increased prevalence of risk factors such as hypertension and diabetes (Andrade et al. 2014; Chugh et al. 2014) . AF has important clinical consequences, negatively affecting quality of life and doubling cardiovascular morbidity and mortality (Kirchhof et al. 2016) . Currently available pharmacological anti-AF therapies are only moderately effective, and their use is limited by severe adverse effects, including ventricular proarrhythmia and extracardiac toxicity (Calvo et al. 2018; Dan and Dobrev 2018; Lafuente-Lafuente et al. 2015) . The limited efficacy of these pharmacological agents is likely due to a one-size-fits-most approach despite the diverse etiology of AF, which can occur in a wide range of conditions as the result of multiple pathologic processes, including Ca 2+ -handling abnormalities, electrical remodeling, structural remodeling, and autonomic imbalance (Heijman et al. 2016; Heijman et al. 2018; Nattel and Harada 2014) . In addition, the high prevalence of asymptomatic AF hinders AF detection and initiation of anti-AF therapies early during the disease process, when AF is still amenable to therapy (Boriani et al. 2015; Siontis et al. 2016) .
AF can also be promoted by increased inflammatory signaling and systemic inflammatory disease (Lazzerini et al. 2014; Lindhardsen et al. 2012; Yao et al. 2018) , including rheumatoid arthritis (RA). In a Danish nationwide cohort study (Lindhardsen et al. 2012) , the incidence of AF was 40% higher in RA patients compared to the general population, with higher relative risks in younger patients. Similarly, Kim et al. (2014) reported an AF incidence-rate ratio of 1.4 in RA patients, although this association disappeared after correcting for a wide range of other cardiovascular risk factors. Thus, the higher propensity of AF in RA may be attributed to several pathophysiological mechanisms, involving both direct and indirect effects of systemic inflammation on the atria. The indirect AF-promoting effects include the development of heart failure and ischemic heart disease, which subsequently initiate atrial structural, autonomic, and electromechanical remodeling (Dai et al. 2017; Lazzerini et al. 2014; Li and Dobrev 2018; Nattel and Harada 2014) . Furthermore, increased arterial stiffness and drugs used for the treatment of RA may also modulate the interaction between RA and AF (Lindhardsen et al. 2012) . Thus, acute and chronic inflammation can directly promote AF through several pathways. Studies on the mechanisms of postoperative AF have shown that acute inflammation can induce AF by promoting cellular oxidative stress via pro-inflammatory cytokines (see Fig. 1 ) (Lubbers et al. 2015; Maesen et al. 2012) . Conversely, chronic inflammation promotes AF through atrial structural remodeling, particularly the development of atrial fibrosis (Abe et al. 2018; Chen et al. 2018 ).
In the current issue of Naunyn-Schmiedeberg's Archives of Pharmacology, Zhang and colleagues (Zhang et al. 2018) investigated the effect of resveratrol, a bioactive polyphenol commonly found in wine, grapes, mulberries, and peanuts (Baczko and Light 2015) , on atrial structural and metabolic remodeling, as well as AF-susceptibility, in rats with collagen-induced arthritis (CIA). AF inducibility and duration were markedly elevated in CIA rats and were accompanied by increased atrial levels of IL-6 and TNF-α, as well as atrial apoptosis and fibrosis. CIA also downregulated the AMPK/PGC-1α pathway, suggesting dysregulation of atrial metabolism. Zhang et al. (2018) also showed that 4 weeks of resveratrol treatment started 3 weeks after the second collagen injection could attenuate all proarrhythmic components of the CIA-induced substrate and significantly reduced the incidence and duration of burst-pacing-induced AF.
Resveratrol is a natural polyphenol derivative that has been widely investigated and is believed to have cardioprotective and antiarrhythmic properties (Baczko and Light 2015; Baczko et al. 2014; Frommeyer et al. 2018; Liu et al. 2017; Trevino-Saldana and Garcia-Rivas 2017) . Consistent with the findings by Zhang et al. (2018) , several studies have shown that resveratrol is also a promising pharmacological agent for the treatment of AF (Baczko and Light 2015) . However, the potential mechanisms underlying the anti-AF effects of resveratrol are diverse (Fig. 1) , and their relative contribution in different forms of AF is unknown.
Resveratrol can alter cardiac electrophysiology and arrhythmogenesis through a direct effect on cardiac ion channels, including inhibition of the peak and late components of cardiac voltage-gated Na + channels (Baczko and Light 2015; Frommeyer et al. 2018 ). Resveratrol increases myofilament Ca 2+ sensitivity but inhibits L-type Ca 2+ currents, resulting in a decreased Ca 2+ transient amplitude (Liu et al. 2017) . It also inhibits phosphodiesterases, enhancing the inotropic effect of sympathomimetic agents, while inhibiting their proarrhythmic effects (Hernandez-Cascales 2017). Acute resveratrol treatment reduces the number of inducible AF episodes in an ex vivo rabbit AF model, without significant reduction in AF susceptibility (Frommeyer et al. 2018 ). In this model, resveratrol induces slowing of intrinsic heart rate, slowing of conduction velocity, and prolongation of atrial effective refractory period (aERP). Similarly, a resveratrol derivative with increased affinity for Kv1.5, underlying the atrial-specific ultrarapid delayed-rectifier K + current, has been shown to prolong aERP and reduce the duration of AF episodes in a dog model of atrial tachycardia remodeling (Baczko et al. 2014 ). This resveratrol-derived small molecule did not prolong ventricular repolarization, suggesting a low risk for Torsade de Pointes as a complication of AF treatment (Baczko et al. 2014 ). AF inducibility is also increased in a rabbit model of coronary-ligation-induced heart failure, but in this model, atrial ERP is prolonged and both AF inducibility and ERP are decreased by acute application of resveratrol. Similarly, acute resveratrol application reduces ventricular ERP in guinea pig ventricular cardiomyocytes (Liew et al. 2005) . In contrast, in the study by Zhang et al. (2018) , long-term treatment with resveratrol did not significantly affect aERP in CIA rats. The latter may be due to species-, chamber-, or disease-specific effects, as well as compensatory electrical remodeling during long-term treatment, which is absent during acute resveratrol application.
Indeed, long-term resveratrol treatment can have antiarrhythmic effects by preventing atrial remodeling. For example, 1 week of daily resveratrol treatment, initiated 4 weeks after coronary ligation in the rabbit heart failure module attenuates atrial apoptosis and fibrosis and, partially, normalizes mRNA levels of several ion channels, as well as protein levels of SERCA2a and phospholamban, through a PI3K/AKT/ eNOS pathway (Chong et al. 2015) . Consistent with this normalization of atrial electrical, Ca 2+ -handling and structural remodeling, long-term resveratrol treatment also reduced AF inducibility. Resveratrol also attenuates hypertrophic remodeling and can prevent the development of heart failure through modulation of Ca 2+ -signaling pathways, notably by inhibiting calcineurin and Ca 2+ /calmodulin-dependent protein kinase-II (CaMKII) activation (Baczko and Light 2015; Liu et al. 2017) , which may both directly and indirectly affect atrial remodeling. For example, in rats with aortic banding, longterm resveratrol treatment prevents Ca 2+ -handling remodeling, including increased CaMKII expression and autophosphorylation, as well as fibrosis and ventricular dilation (Dong et al. 2014; Liu et al. 2017) . Finally, resveratrol is a potent anti-oxidant, reducing cellular oxidative stress, which represents a major trigger for electrical and Ca 2+ -handling abnormalities, including hyperactive ryanodine receptormediated sarcoplasmic reticulum Ca 2+ releases that may initiate AF (Liu et al. 2017) , as well as for metabolic and structural remodeling (Harada et al. 2017; Harada et al. 2015) . In agreement, in the study by Zhang et al. (2018) , resveratrol restores the CIA-induced decrease in phosphorylation and expression of AMPK, normalizing atrial metabolism, including the expression of PGC-1α, an important regulator of mitochondria bioenergetics, and the main energy transport proteins Glut4 and FAT/CD36 (Zhang et al. 2018) . These alterations, together with the reduction in atrial inflammation, likely contribute to the resveratrol-induced decrease in cellular apoptosis and fibrosis observed in this study. Taken together, the work by Zhang et al. (2018) suggests that resveratrol can prevent the development of AF-maintaining structural remodeling through beneficial modulation of atrial inflammation and metabolism.
Despite the potential of resveratrol as antiarrhythmic agent, several questions need to be addressed. Firstly, although Zhang et al. (2018) show that resveratrol can suppress the progression of the AF-promoting substrate that develops during the final 4 weeks of drug administration initiated 3 weeks after the last collagen injection, the magnitude of atrial remodeling generated before the administration of resveratrol is unknown. Typically, notable atrial structural remodeling only develops after 8-14 weeks of interventions (Dai et al. 2017; Kim et al. 2011) . Thus, it is unclear whether resveratrol can Bonly^prevent the development of atrial remodeling or can actually revert existing atrial structural remodeling, which would be more clinically relevant, since resveratrol will likely be prescribed to patients who already have a significant degree of atrial remodeling. Secondly, resveratrol has a limited halflife (± 49 min in normal individuals (Amiot et al. 2013; Baczko and Light 2015) ), as it is rapidly metabolized and cleared from the body, making it unsuitable for oral administration. Although this half-life can be improved (Amiot et al. 2013) , achieving a stable pharmacokinetic profile may still be challenging due to accompanying systemic diseases that commonly develop together with RA-induced AF, including impaired renal function and other autoimmune disorders (Kochi et al. 2018) . Thirdly, although resveratrol is generally considered a safe drug, its electrophysiological effects may still present a potential arrhythmogenic risk, particularly at high concentrations (Liu et al. 2017; Trevino-Saldana and GarciaRivas 2017) . For example, polydatin, a drug highly similar to resveratrol, increases ryanodine receptor activity, leading to more Ca 2+ sparks and proarrhythmic spontaneous Ca 2+ releases from the sarcoplasmic reticulum (Liu et al. 2017) . Finally, most of the antiarrhythmic effects of resveratrol have only been documented in animal models. Although some indirect studies have hinted at a beneficial effect of resveratrol in patients, this has been questioned by recent randomized controlled trials (Kjaer et al. 2017) . Whether the same antiarrhythmic effects observed with resveratrol in animal models can also be achieved in AF patients (either with or without RA) is unknown, which highlights the importance of future investigations of such effects in patient samples and clinical studies. Taken together, resveratrol represents a potentially novel antiarrhythmic agent with an apparently strong safety profile. Many publications have shown that resveratrol targets, either directly or indirectly, multiple substrates involved in the initiation and maintenance of AF, including Ca 2+ -handling abnormalities and atrial electrical and structural remodeling. Thus, resveratrol may offer new therapeutic approaches for different forms of AF, including AF in the setting of RA. However, despite the potential of resveratrol, extensive further experimental research and clinical trials are needed to confirm these antiarrhythmic effects in patients with AF.
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